Jade Biosciences, Inc.: Bellevue Group AG amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Bellevue Group AG amended its Schedule 13G filing for Jade Biosciences, Inc., updating its disclosed stake in the company with the SEC under accession number 0001104659-26-128591. The amendment signals a change in the institutional investor's reported position, though the filing did not specify the size or direction of the adjustment. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or when previously reported holdings change materially. Investors will watch for further 13G or 13D filings to gauge whether Bellevue's position continues to shift.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Jade Biosciences, Inc., Bellevue Group AG